Bio­gen lines up po­ten­tial deal for ALS drug, dou­bling down on neu­ro­fil­a­ment bio­mark­er

Hav­ing scored a his­toric FDA ac­cel­er­at­ed ap­proval in amy­otroph­ic lat­er­al scle­ro­sis, or ALS, based on a bio­mark­er, Bio­gen is go­ing for more.

Bio­gen has teamed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER